Page last updated: 2024-10-30

letrozole and Fatty Liver

letrozole has been researched along with Fatty Liver in 1 studies

Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.

Research Excerpts

ExcerptRelevanceReference
"Among 1203 subjects who were taking adjuvant TMX or AI (anastrozole or letrozole) without fatty liver at baseline, those taking TMX or AI were 1:1 matched on the propensity score."7.85Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study. ( Hong, N; Kim, SI; Park, S; Rhee, Y; Seo, DH; Sohn, JH; Yoon, HG, 2017)
"Among 1203 subjects who were taking adjuvant TMX or AI (anastrozole or letrozole) without fatty liver at baseline, those taking TMX or AI were 1:1 matched on the propensity score."3.85Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study. ( Hong, N; Kim, SI; Park, S; Rhee, Y; Seo, DH; Sohn, JH; Yoon, HG, 2017)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hong, N1
Yoon, HG1
Seo, DH1
Park, S1
Kim, SI1
Sohn, JH1
Rhee, Y1

Other Studies

1 other study available for letrozole and Fatty Liver

ArticleYear
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 82

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast

2017